Gilead Sciences, Inc. is calling for more transparency on how the National Health Service (NHS) in England arrived at figures on the cost of delivering CAR-T therapies to patients. The company's Gordon Lundie has warned that if the health technology appraisal body NICE continues to accept these costs, it will be impossible for companies selling CAR-T therapies to offer a price that NICE regards as cost effective.
In July, NICE issued draft guidance rejecting Kite’s CAR-T therapy Yescarta (axicabtagene ciloleucel) for treating adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?